Hartford HealthCare - Avon

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Bladder cancer1 trial
• Gastric and oesophageal cancer1 trial
• Kidney cancer1 trial
• Lung cancer1 trial
• Ovarian cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 35 trials
• Phase 2/31 trial

Status

• Recruiting6 trials

Lead sponsor

• Alliance for Clinical Trials in Oncology2 trials
• National Cancer Institute (NCI)2 trials
• NRG Oncology1 trial
• SWOG Cancer Research Network1 trial

Running trials

• Recruiting

  Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  NCT06498635· Phase 3· National Cancer Institute (NCI)· Source

  Contact: Krishna S. Gunturu (principal investigator)

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

  Contact: Michael Sun (principal investigator)

• Recruiting

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source

  Contact: Michael Sun (principal investigator)

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

  Contact: Rajvi Patel (principal investigator)

• Recruiting

  Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

  NCT05929768· Phase 3· SWOG Cancer Research Network· Source

  Contact: Wylie D. Hosmer (principal investigator)

• Recruiting

  mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  NCT05677490· Phase 3· Alliance for Clinical Trials in Oncology· Source

  Contact: Jaykumar T. Thumar (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting